Peptide Vaccine Against ADAMTS-7 Ameliorates Atherosclerosis and Postinjury Neointima Hyperplasia-Reference-Cited by-同舟云学术

Peptide Vaccine Against ADAMTS-7 Ameliorates Atherosclerosis and Postinjury Neointima Hyperplasia

Published:2023-02-28 Issue:9 Volume:147 Page:728-742
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Ma Zihan¹²,Mao Chenfeng¹²³,Chen Xiao⁴⁵,Yang Shiyu¹²,Qiu Zhihua⁴⁵,Yu Baoqi⁶⁷,Jia Yiting¹²^ORCID,Wu Chao⁸,Wang Yiyi⁴⁵,Wang Yuhui⁹,Gu Rui¹²,Yu Fang¹²,Yin Yanhui¹⁰¹¹,Wang Xian¹²,Xu Qingbo¹²¹³^ORCID,Liu Chuanju¹⁴,Liao Yuhua⁴⁵,Zheng Jingang⁸,Fu Yi¹²,Kong Wei¹²^ORCID

Affiliation:

1. Department of Physiology and Pathophysiology (Z.M., C.M., S.Y., Y.J., R.G., F.Y., X.W., Y.F., W.K.), Peking University, Beijing, China.

2. Key Laboratory of Molecular Cardiovascular Science (Z.M., C.M., S.Y., Y.J., R.G., F.Y., X.W., Y.F., W.K.), Ministry of Education, Beijing, China.

3. Beijing Institute of Biotechnology, Beijing, China (C.M.).

4. Department of Cardiology and Institute of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (X.C., Z.Q., Yiyi Wang, Y.L.).

5. Key Laboratory of Molecular Biological Targeted Therapies, Ministry of Education, Wuhan, China (X.C., Z.Q., Yiyi Wang, Y.L.).

6. Key Laboratory of Remodeling-Related Cardiovascular Diseases (B.Y.), Ministry of Education, Beijing, China.

7. Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China (B.Y.).

8. Department of Cardiology, Peking University China-Japan Friendship School of Clinical Medicine, Beijing, China (C.W., J.Z.).

9. School of Basic Medical Sciences, Institute of Cardiovascular Sciences and Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education (Yuhui Wang), Peking University, Beijing, China.

10. Department of Immunology (Y.Y.), Peking University, Beijing, China.

11. Key Laboratory of Medical Immunology of Ministry of Health (Y.Y.), Peking University, Beijing, China.

12. School of Cardiovascular Medicine and Sciences, King’s College London British Heart Foundation Centre, United Kingdom (Q.X.).

13. Department of Cardiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China (Q.X.).

14. Department of Orthopedic Surgery, Department of Cell Biology, New York University School of Medicine, New York, NY (C.L.).

Abstract

Background: The metalloprotease ADAMTS-7 (a disintegrin and metalloproteinase with thrombospondin type 1 motif 7) is a novel locus associated with human coronary atherosclerosis. ADAMTS-7 deletion protects against atherosclerosis and vascular restenosis in rodents. Methods: We designed 3 potential vaccines consisting of distinct B cell epitopic peptides derived from ADAMTS-7 and conjugated with the carrier protein KLH (keyhole limpet hemocyanin) as well as aluminum hydroxide as an adjuvant. Arterial ligation or wire injury was used to induce neointima in mice, whereas ApoE -/- and LDLR -/- (LDLR [low-density lipoprotein receptor]) mice fed a high-fat diet were applied to assess atherosclerosis. In addition, coronary stent implantation was performed on vaccine-immunized Bama miniature pigs, followed by optical coherence tomography to evaluate coronary intimal hyperplasia. Results: A vaccine, ATS7vac, was screened out from 3 candidates to effectively inhibit intimal thickening in murine carotid artery ligation models after vaccination. As well, immunization with ATS7vac alleviated neointima formation in murine wire injury models and mitigated atherosclerotic lesions in both hyperlipidemic ApoE -/- and LDLR -/- mice without lowering lipid levels. Preclinically, ATS7vac markedly impeded intimal hyperplasia in swine stented coronary arteries, but without significant immune-related organ injuries. Mechanistically, ATS7vac vaccination produced specific antibodies against ADAMTS-7, which markedly repressed ADAMTS-7–mediated COMP (cartilage oligomeric matrix protein) and TSP-1 (thrombospondin-1) degradation and subsequently inhibited vascular smooth muscle cell migration but promoted re-endothelialization. Conclusions: ATS7vac is a novel atherosclerosis vaccine that also alleviates in-stent restenosis. The application of ATS7vac would be a complementary therapeutic avenue to the current lipid-lowering strategy for atherosclerotic disease.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference54 articles.

1. Epidemiology of cardiovascular disease in China: current features and implications

2. Atherosclerosis

3. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

4. Restenosis after PCI. Part 1: pathophysiology and risk factors

5. Restenosis after PCI. Part 2: prevention and therapy

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in Omics and Breakthrough Gene Therapies: A Glimpse into the Future of Peripheral Artery Disease;Annals of Vascular Surgery;2024-10

2. Hypertension research 2024 update and perspectives: basic research;Hypertension Research;2024-09-09

3. Tudor-SN exacerbates pathological vascular remodeling by promoting the polyubiquitination of PTEN via NEDD4-1;Journal of Biomedical Science;2024-09-05

4. ECM Microenvironment in Vascular Homeostasis: New Targets for Atherosclerosis;Physiology;2024-09-01

5. Nanoparticles targeting OPN loaded with BY1 inhibits vascular restenosis by inducing FTH1-dependent ferroptosis in vascular smooth muscle cells;Biomaterials;2024-09